🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Formulation C

Found 0 matching trials

Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation

PHASE1

The purpose of this trial is to determine the equivalence of 3 new formulat...

Status

Completed

Location

Multiple Locations

Start Date

2008-02

Trial ID

NCT00630435

Treatments Being Tested

Premarin®/MPA formulation A Premarin®/MPA formulation B Premarin®/MPA formulation C Premarin®/MPA currently marketed product

A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production

PHASE1

A safety study to compare the effect of two different formulations of PrEP-...

Status

Completed

Location

Quotient Clinical

Start Date

2017-05-08

Trial ID

NCT03198676

Treatments Being Tested

PrEP-001 6.4 mg PrEP-001 6.4 mg PrEP-001 3.2 mg Placebo

A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein

PHASE1

The main purpose of this study is to investigate how quickly and to what ex...

Status

Completed

Location

PRAHealthSciences

Start Date

2018-12-13

Trial ID

NCT03773068

Treatments Being Tested

BAY1817080 - Formulation A BAY1817080 - Formulation B [13C715N]-BAY 181708 stable isotope label (SIL)

A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects

PHASE1

This is an open-label, 2-arm, single-dose, randomized crossover study. The ...

Status

Completed

Location

Multiple Locations

Start Date

2014-09

Trial ID

NCT02279485

Treatments Being Tested

Perampanel

Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure

Conversion of dietary nitrates to nitric oxide (NO) is a non-canonical path...

Status

Completed

Location

The Hypertension Institute

Start Date

2023-06-24

Trial ID

NCT05928676

Treatments Being Tested

Vascanox® HP

A Phase I Study Comparing the Safety, Pharmacokinetics and Renal Effects of VRP-034 and Marketed Polymyxin B in Healthy Volunteers

PHASE1

This is a Phase 1, single-center, randomized, double-blind, active-controll...

Status

Not Yet Recruiting

Location

Veeda Clinical Research Ltd

Start Date

2026-04

Trial ID

NCT07502144

Treatments Being Tested

VRP-034 (Polymyxin B 500,000 IU)Commercially available Polymyxin B 500,000 IU (Poly-MxB)

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

PHASE3

This study has been designed to evaluate whether "anti-angiogenesis" therap...

Status

Completed

Location

University of Arkansas for Medical Sciences/MIRT

Start Date

1998-08

Trial ID

NCT00083551

Treatments Being Tested

Thalidomide Ara-C BCNU Cisplatin Cytoxan Dexamethasone Doxorubicin Etoposide Filgrastim Recombinant GM-CSF Interferon-alpha-2b Melphalan Vincristine

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

PHASE1

* To evaluate the pharmacokinetic (PK) profiles of MIN-l0l following admini...

Status

Completed

Location

Biokinetic Europe

Start Date

2016-11-30

Trial ID

NCT03038646

Treatments Being Tested

MIN-101

Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants

PHASE1

The purpose of this study is to evaluate in a double-blinded fashion the ta...

Status

Completed

Location

Multiple Locations

Start Date

2016-06

Trial ID

NCT02813460

Treatments Being Tested

Formulation A (ALS-008176)Formulation B (ALS-008176)Formulation C (ALS-008176)Formulation D (ALS-008176)Formulation E (ALS-008176)Formulation F (ALS-008176)Formulation G1 (ALS-008176)Formulation G2 (ALS-008176)Formulation G3 (ALS-008176)Formulation H1 (ALS-008176)Formulation H2 (ALS-008176)Formulation H3 (ALS-008176)

Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

PHASE1

This is a Phase 1, randomized, open label, 2 treatment, 2 period, 2-way cro...

Status

Completed

Location

Premiere Oncology

Start Date

2010-07

Trial ID

NCT01149720

Treatments Being Tested

Tivantinib (ARQ 197) Capsule Tivantinib (ARQ 197) Tablet Tivantinib (ARQ 197) Capsule D, oral

Previous Next